BOSTON, MA, USA I 11, 2024 I Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...

Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway ...

WILMINGTON, DE, USA I 11, 2024 I Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) ...

TOKYO, USA & NOVI, MI, USA & DÜSSELDORF, Germany I 11, 2024 I Asahi Kasei Pharma has taken another step in its transformation into a global ...

ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...

Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR ...

SAN DIEGO, CA, USA I 11, 2024 I AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology ...

Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease ...

COPENHAGEN, Denmark I 10, 2024 IZealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery ...

STOCKHOLM, Sweden I 10, 2024 I Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the ...

PANGYO, South Korea I 10, 2024 I Huonslab, a subsidiary of Huons Global (KOSDAQ: 084110), announced today the successful enrollment and ...

LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences ...